Global Hematological Malignancies Emerging Therapeutics Market 2023

Global Hematological Malignancies Emerging Therapeutics Market 2023

Description
The global hematological malignancies emerging therapeutics industry is projected to grow at a CAGR of 11.2% from 2023 to 2029. The market was valued at $10.79 billion in 2022 and is expected to reach $23.27 billion by 2029. Pharmaceutical companies' interest in developing therapies for hematological malignancies has driven market advancements. Monoclonal antibodies have been widely used, but there is an anticipated increase in the use of CAR-T cell therapy. Factors driving market growth include the rising prevalence of hematological malignancies, favorable regulatory environment, and adoption of precision medicine. Challenges include high therapy costs, reimbursement issues, and safety concerns. The market report covers clinical findings, financing opportunities, market outlook, and clinical trial landscape for mAB and CAR-T cell therapies in hematological malignancies.

Market Segmentation
The market is segmented based on various factors, including marketed drug, potential pipeline product, indication, and region.

Segmentation by Marketed Drug
Monoclonal Antibodies
CAR-T Cell Therapy

Segmentation by Potential Pipeline Product
Monoclonal Antibodies
CAR-T Cell Therapy

Segmentation by Indication
Leukemia
Lymphoma
Multiple Myeloma

Segmentation by Region
North America - U.S. and Canada
Europe - Germany, U.K., France, Italy, and Spain
Asia-Pacific - China, Japan, and South Korea
Rest-of-the-World

The marketed drugs segment is projected to witness a CAGR of 11.2% from 2023 to 2029, driven by the commercialization of monoclonal antibodies and CAR-T cell therapy products for hematological malignancies. Monoclonal antibodies accounted for 86.1% of the market in 2022, but CAR-T cell therapy is expected to grow rapidly with a CAGR of 16.1% during the forecast period.

The success of monoclonal antibodies can be attributed to continuous innovations in treating hematological malignancies. Revenue from these drugs includes Blincyto, Besponsa, Lumoxiti, Mylotarg, Opdivo, AiRuiKa, Tyvyt, Tislelizumab, Gazyva, Zynlonta, Darzalex, Blenrep, Keytruda, and Adcetris.

Darzalex targets CD38 proteins on plasma cells, inhibiting growth and initiating apoptosis. It was developed by Genmab A/S and Johnson & Johnson Services, Inc. and gained approvals for multiple myeloma treatment.

By 2029, monoclonal antibodies are projected to hold 71.5% of pipeline products, while CAR-T cell therapy will hold 28.5%. CAR-T cell therapy shows promise in hematologic malignancies.

Researchers are investigating drugs for leukemia, multiple myeloma, and lymphoma to develop potent therapies. Multiple myeloma had the largest market share in 2022, accounting for 49.6% of cases, and is projected to grow at a CAGR of 9.1%.

North America had the largest market share in 2022 due to research and development activities and the prevalence of hematological malignancies. However, the Asia-Pacific region is expected to have the highest CAGR of 11.7% from 2023 to 2029.

Competitive Landscape
Companies profiled in this report include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.